Topic: acute myeloid leukemia (AML)
The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Two dual EGFR/HER2 inhibitors from Boehringer Ingelheim and Puma showed in vitro activity against AML cancer cells.
Tolero Pharmaceuticals has inked a pact to test its CDK9 inhibitor, alvocidib, in combination with AbbVie’s Venclexta in relapsed/refractory AML.
NewLink has cut its headcount by a third to buy the time it needs to prove that—despite setbacks—its IDO inhibitor indoximod is still worth pursuing.
The DNA hypomethylating agent failed to beat the complete response or overall survival rates achieved in the control arm.
Phase 3 results with Daiichi Sankyo's new FLT3 inhibitor quizartinib put it on course for regulatory filings in acute myeloid leukemia.
The AACR conference featured data on promising new approaches to CAR-T treatments and stimulating cancer-killing immune cells.
Bellicum reported encouraging data for its BPX-501, but its U.S. program remains under a clinical hold.
Roche joins Merck KGaA as pharma parter for Forty Seven's CD47-targeting antibody, which blocks a "don't eat me" signal sent out by malignant cells.
The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.